Clinical trial of docetaxel in the treatment of advanced gastric cancer
10.13699/j.cnki.1001-6821.2016.14.010
- VernacularTitle:多西紫杉醇治疗晚期胃癌患者的临床研究
- Author:
Yun-Hui DIAO
1
;
Meng XUE
;
Jin-Ping SHA
;
Hong-Wei FAN
;
Hai-Xia WANG
Author Information
1. 南阳市中心医院消化内科
- Keywords:
docetaxel;
advanced gastric cancer;
carcinoma embryonic antigen;
carbohydrate antigen 199;
clinical efficacy;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(14):1283-1285
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of do-cetaxel in the treatment of advanced gastric cancer .Methods Eighty-five patients with advanced gastric cancer were randomly divided into control group (n=42) and treatment group (n=43).Control group was given irinotecan hydrochloride 60 mg? m-2 , day 1 +60 mg? m-2 cisplatin, intravenous infusion, day 1.Treatment group was given 40 mg? m-2 docetaxel , intravenous infusion , day 1.Two groups were trea-ted for 4 courses with 7 d per course.The total effective rate , levels of carcinoembryonic antigen ( CEA ) and carbohydrate antigen 199 ( CA199 ) , incidence of adverse drug reactions were compared between two groups.Results After treatment, the total effective rate in treatment group was 93.02%(40/43), which was significantly higher than that in control group [69.05%(29/42), P <0.05] .After treatment, the serum levels of CEA were ( 37.61 ±5.87 ) , ( 59.73 ±6.97 )μg? L-1 and CA199 were ( 49.25 ±6.83 ) , ( 98.23 ±14.63 ) U? L-1 in the treatment and control group .And those indexes after treatment in treat-ment group were significantly lower than those in control group (P<0.05).The adverse drug reactions were based on gastrointestinal reactions and bone marrow suppression for two groups .Also, the inci-dence of adverse drug reactions was not statistically significant in the two groups ( 9.30% vs 16.67%, P >0.05 ) .Conclusion Docetaxel has a definitive clinical efficacy for the treatment of advanced gastric cancer , which was better than irinotecan hydrochloride combined with cisplatin , without increasing the incidence of adverse drug reactions .
